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The development of stable and long-circulating liposomes provides protection of the 
drug cargo from degradation and increases tumor drug delivery, leading to the design 
of liposome formulations with great potential in cancer therapy. However, despite the 
sound pharmacologic basis, many liposomal as well as other nanoparticle-based drug 
formulations have failed to meet regulatory criteria for approval. The question that arises 
is whether we have missed key liposome–host interactions that can account for the gap 
between the major pharmacologic advantages in preclinical studies and the modest 
impact of the clinical effects in humans. We will discuss here the nanoparticle–immune 
system interactions that may undermine the antitumor effect of the nanodrug formulations 
and contribute to this gap. To overcome this challenge and increase clinical translation, 
new preclinical models need to be adopted along with comprehensive immunopharma-
cologic studies and strategies for patient selection in the clinical phase.
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iNtrODUctiON
In the field of nanomedicine, liposomes are the most common nanocarrier platforms among 
the approved agents and those under clinical investigation. The development of stable and long-
circulating liposomes provides protection of the drug cargo from degradation (1) and increases 
tumor drug delivery by exploiting the enhanced permeability and retention (EPR) effect (2). This has 
led to the design of liposome formulations with great potential in cancer therapy. However, despite 
the sound pharmacologic basis, many of the liposomal drugs as well as other nanoparticle-based 
drug formulations have failed to meet regulatory criteria for approval or have shown modest effects 
in phase 3 clinical studies (3–8). In fact, some of the approvals have been based on reduced toxicity 
rather than increased efficacy. A recent meta-analysis of 14 randomized clinical trials that directly 
compared the anticancer efficacy of liposomal cytotoxic chemotherapy to their conventional “free” 
drug formulation found that liposome encapsulation of drugs did not improve objective response 
rates, progression-free survival, or overall survival in cancer patients (6). This highlights a major 
roadblock: despite the pharmacological advantages of improved drug delivery, liposome-mediated 
therapies have largely failed to increase anticancer efficacy over conventional formulations. Yet, they 
remain attractive delivery platforms due to their ability to considerably improve drug tolerability 
and decrease toxicity in cancer patients. The question that arises is whether we have missed some 
FigUre 1 | cancer regression or progression as a result of complex interactions between the immune, tumor, and carrier-drug systems. PK, 
pharmacokinetics; MOA, mechanisms of action; EPR, enhanced permeability and retention; CARPA, complement activation-related pseudoallergy.
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liposome–host interactions that can account for the gap between 
the major pharmacologic advantages in preclinical studies, on the 
one hand, and the modest impact of the clinical effects in humans, 
on the other hand. We will discuss here the possibility that some 
nanoparticle–immune system interactions may undermine the 
antitumor effect of the nanodrug formulations and contribute to 
this gap (Figure 1).
cLiNicAL eviDeNce OF NANOPArticLe–
iMMUNe iNterActiONs
Nanoparticles are known to interact with the innate immune 
system, including the complement system and the mononuclear 
phagocyte system (MPS) to varying extents, and these interactions 
with the immune system have significant clinical consequences. 
They can activate circulating complement proteins (9, 10), lead-
ing sometimes to an infusion reaction known as complement 
activation-related pseudoallergy (CARPA). Blood complement 
activation by pegylated liposomal doxorubicin (PLD) has been 
implicated as the cause of acute infusion reactions in cancer 
patients (11). Importantly, it has been reported that polymer 
nanoparticles that activate the complement system can promote 
tumor growth through generation of C5a (12), a complement 
anaphylatoxin that has been shown to induce tumor growth via 
recruitment of myeloid-derived suppressor cells (MDSCs) (13). 
Nonetheless, the clinical relevance of this is unclear since the 
nanoparticles in these studies were engineered to activate com-
plement, whereas all clinically relevant nanoparticles have been 
designed to limit complement activation. Furthermore, while 
most nanoparticles still activate blood complement proteins to 
some extent, it is not known whether and how much they activate 
complement in the tumor microenvironment.
In addition to the complement system, the MPS is known 
to interact extensively with nanoparticles. The MPS is com-
prised primarily of monocytes and macrophages in the blood, 
spleen, and liver. These cells, especially when activated, have high 
phagocytic capacity and normally function to scavenge and clear 
cellular debris, damaged/apoptotic cells, and foreign materials 
including bacteria, viruses, and nanoparticles. In cancer patients, 
peripheral blood monocyte count was found to correlate with 
PLD clearance rates: a decrease in monocyte count was associ-
ated with a decrease in clearance rate (14), suggesting a direct 
relationship between functionality of the MPS and nanoparticle 
drug pharmacokinetics (PK). This was further supported by a 
subsequent clinical study showing that phagocytic capacity of the 
MPS, as measured by in vivo technetium sulfur colloid uptake, 
correlated with liposome clearance rates in patients (15).
In addition to clearance of debris and foreign particles, the 
MPS also regulates the adaptive immune response through the 
antigen-presentation functions of dendritic cells and can stimu-
late or inhibit T cell proliferation and cytokine responses (16). 
Hence, it is in theory possible for nanoparticle interactions with 
the innate immune system to impact adaptive immunity. For 
example, PLD has been reported to suppress patient sensitization 
and allergic reactions to carboplatin in patients receiving a com-
bination of both the drugs (17), suggesting that PLD liposomes 
may have direct or indirect suppressive effects on lymphocytes. 
However, overall, the interactions between nanoparticles and 
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the adaptive immune system have received comparatively little 
attention in clinical trials of carrier-mediated anticancer drugs. 
One application of nanomedicine that is focused on the adap-
tive immune system is the use of nanoparticles as vehicles to 
deliver antigens and boost their immunogenicity as vaccines. 
The particles used in this context are designed to exploit uptake 
by antigen-presenting cells, mostly dendritic cells, and thereby 
enabling induction of antigen-specific adaptive immunity (18). 
While it is difficult to generalize findings from this field to the 
cancer drug delivery field, it is clear that nanoparticles have 
the potential to modulate immune status at the interface between 
the innate and adaptive immune system.
When considering immunomodulatory carrier-mediated 
effects, one liposome component that stands out is the polyethylene 
glycol (PEG) polymer coating used in many liposomal formula-
tions (19). PEG is well known for reducing immunogenicity (20) 
and for its immunocamouflage properties (21). PEG-modification 
(pegylation) is generally believed to diminish complement acti-
vation responses and evade clearance by the immune system, 
thereby enabling long circulation of nanoparticles (22). However, 
PEG has also been found to induce complement activation in this 
scenario as well (23). In preclinical models, accelerated blood 
clearance (ABC) of subsequent doses of pegylated liposomes 
was observed in animals, and this has been associated with the 
production of anti-PEG antibodies (24). However others have 
attributed the ABC phenomenon to non-specific binding of PEG 
to complement proteins, leading to complement activation and 
subsequent clearance of the particles (25). The clinical relevance 
of these findings is unclear. Preexisting anti-PEG antibodies may 
be present in 56–72% of the general population (26), yet the ABC 
phenomenon has not been reported in humans. Interestingly, 
the opposite effect, decreased clearance of subsequent doses of 
doxorubicin-loaded pegylated liposomes, was seen in cancer 
patients (27). Nonetheless, these reports strongly support a role 
for PEG in the immunopharmacology of liposome-mediated 
drugs and highlight critical gaps in current understanding of 
the mechanisms of PEG–immune interactions in the setting of 
cancer drug delivery.
POteNtiAL iMPAct ON cANcer 
PrOgressiON AND regressiON
It is evident that nanoparticle interactions with the immune sys-
tem affect drug tolerability, immunogenicity, and PK. However, 
their impact on anticancer efficacy remains to be elucidated. 
The tumor microenvironment is complex, and tumors are often 
infiltrated by immune cells such as monocytes, macrophages, 
and MDSCs, which are believed to have protumoral functions 
through their inhibition of T  cell antitumor responses and 
enhancement of tumor angiogenesis (28, 29). Interestingly, it 
was recently reported that a pegylated liposomal drug carrier, 
similar to that used in patients, significantly enhanced tumor 
growth in a mouse model of HPV-induced cancer (30). This was 
associated with suppression of antitumor immunity as indicated 
by decreased interferon-γ production by tumor-associated mac-
rophages and cytotoxic T cells, diminished tumor infiltration of 
tumor antigen-specific T cells, and decreased number of dendritic 
cells in tumor-draining lymph nodes. It is important to point out 
that these preclinical studies used an immunogenic tumor model 
and liposomes that did not contain any drug cargo. Therefore, 
the clinical relevance of these findings is uncertain since human 
cancers are not always immunogenic, and liposomes always have 
a drug payload that may affect the immune interactions as well. 
Yet, these data suggest that the tumor-promoting potential of the 
carrier may mitigate the benefits of carrier-mediated drug deliv-
ery and could partially explain why there is often an insufficient 
improvement in the clinical efficacy of liposomal drugs over free 
drugs (4, 5, 7, 31). Clearly, more preclinical and clinical research 
efforts are needed to elucidate the precise mechanisms by which 
nanoparticles interact with immune cells, the consequences of 
this interaction on cancer progression, and the impact of the 
drug cargo as well as the tumor immunologic milieu on these 
carrier–immune interactions.
Importantly, recent studies combining liposomal doxorubicin 
with immune modulatory drugs in mouse models of cancer 
suggest that this strategy can overcome carrier-associated immu-
nosuppression and even result in synergistic anticancer effects. 
Co-encapsulation of doxorubicin with alendronate, an amino-
bisphosphonate with immune stimulatory effects, in a pegylated 
liposome showed greater anticancer efficacy than PLD in immu-
nocompetent mouse tumor models (32). Likewise, combining 
PLD with immune checkpoint inhibitors targeting the PD-1 and 
CTLA-4 pathways also resulted in enhanced anticancer efficacy 
as compared to PLD in immunocompetent mice (33). Notably, 
these combination treatment approaches failed to show improved 
efficacy over PLD in immunocompromised mice, supporting the 
pivotal role of the immune system in determining the efficacy 
of the nanomedicine-based anticancer treatments (33). This host 
effect was much less important in the case of some low molecular 
weight drugs such as doxorubicin and gemcitabine. Moreover, 
all but one mouse with complete tumor response following 
PLD treatment rejected a rechallenge with the same tumor cells, 
indicating that they had become immunized (33). Since these 
observations were done with a cargo of doxorubicin, a drug that 
is well known for often leading to immunogenic tumor cell death 
(34), we cannot make extrapolations to other nanomedicines. 
Nonetheless, clinical trials examining the anticancer efficacy of 
combined liposomal chemotherapy with immune checkpoint 
inhibitor antibodies are clearly warranted.
Are We UsiNg tHe rigHt PrecLiNicAL 
MODeLs?
If indeed the liposome carriers and/or their drug payload have 
immunomodulatory effects, then the use of immunocompetent 
mice is critical for observing the full pharmacologic effect. This 
entails the use of mouse syngeneic tumor models, since allogeneic 
xenografts such as human tumors would not grow in immuno-
competent mice. In the last two decades, there has been a shift to 
models based on human tumor xenografts implanted in immu-
nocompromised mice whether athymic mice (lacking T  cells), 
SCID mice (lacking T and B cells), or Beige mice (lacking natural 
killer lymphocytes), the reasoning being that human tumors will 
be more predictive of the activity of new drugs in the clinic. This 
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is probably the case for low molecular weight drugs, but, when 
more complex systems are used such as nanomedicines, the risk 
of overlooking an important interaction with the immune system 
may override any advantage that a human tumor model may offer 
over a syngeneic tumor, as mentioned above (32, 33).
Among the various immunocompetent mouse models, there 
are important distinctions in global immune status (e.g., balance 
of Th1–Th2 cytokines or M1–M2 macrophages) that may affect 
nanoparticle disposition. The Th1-dominant mouse strains 
such as C57BL/6 and B10D2 have been reported to have slower 
rates of clearance of pegylated 300-nm cylindrical hydrogel 
nanoparticles than the Th2-dominant strains such as BALB/c 
and DBA/2 (35). These differences in clearance were correlated 
with increased M1 macrophage polarization and lower particle 
uptake in Th1-dominant strains, and increased M2 macrophage 
polarization and higher particle uptake in the Th2-dominant 
strains. Likewise, when silica nanoparticles were tested in vitro 
with THP1 cells, an immortalized human monocytic cell line, 
alternatively activated (M2-like) THP1 cells demonstrated 
higher nanoparticle uptake than classically activated (M1-like) 
THP1 cells (36). In contrast, another study found that the uptake 
of pegylated or non-pegylated spherical polystyrene nanoparti-
cles by murine bone marrow-derived macrophages is highest in 
classically activated M1 macrophages, followed by alternatively 
activated M2 macrophages, and lowest in unactivated M0 cells 
(37). There is likely no single ideal mouse model, and selection 
should take into consideration the clinical immune characteris-
tics of the host, type of cancer, and type of nanoparticle that are 
being modeled.
To counter the shortfalls of immunocompromised mice as 
hosts of human tumor xenografts, humanized mouse models, in 
which the immune system of SCID mice is reconstituted with 
human bone marrow, have been developed and are being increas-
ingly used particularly in cancer studies that involve immuno-
therapeutic approaches (38). One step further is the use of 
patient-derived tumor xenografts (39), instead of the commonly 
used human tumor cell lines. The testing of nanomedicines in 
humanized mice is still lagging behind but, conceivably, may 
provide an important insight on the interplay of nanomedicines 
with the human immune system.
Another major tumor model factor affecting the testing of 
nanomedicines is the choice between primary tumor implants and 
metastatic tumors. Given that the EPR effect is the main mecha-
nism for selective accumulation of nanomedicines in tumors (2), 
tumor sites with high or poor EPR will respond differently to 
nanomedicines. This is because the degree of EPR appears to be 
dependent on the tumor type and on the site of tumor growth 
(40). Primary tumor implants, particularly those inoculated 
subcutaneously, recruit new blood vessels for growth and usually 
demonstrate high EPR. Less well known is the degree of EPR of 
orthotopically implanted tumors. However, when hematogenous 
metastases occur either by detachment from primary tumors or 
by intravenous injection, tumor cells form multiple and separate 
colonies in lungs and other organs. These tumor colonies grow 
around well-developed and mature blood vessels of the host 
organ and often derive their blood supply by a process known as 
co-option of normal blood vessels, which results in blood vessels 
less permeable and less responsive to antiangiogenic treatments 
and, consequently, less likely to display the EPR effect (41, 42). 
Clearly, given that the clinical challenge is to treat patients with 
metastases, an effort should be made to include metastatic tumor 
models in the testing of nanomedicines to achieve a better predic-
tion of their potential performance in human cancer (43).
Are We UsiNg tHe rigHt cLiNicAL 
triAL DesigNs AND AssessMeNts?
Most, if not all, clinical studies with liposome-based chemo-
therapy and other nanomedicines have been performed with-
out any attempt to select for those cancer patients with tumors 
that display high liposome uptake. This may have contributed 
to some disappointing clinical results. For example, in the 
phase 3 study of PLD against doxorubicin single agent in 
metastatic breast cancer, no survival advantage was observed 
(4) despite the clear superiority of PLD in animal tumor 
models. Recent studies in mouse models using radionuclide 
SPECT imaging with In111-labeled liposomes and PET imaging 
with Zr89-labeled liposomes admixed with PLD have observed 
that higher tumor uptake of liposomes correlates with greater 
antitumor activity at the individual level (44, 45). These stud-
ies also show a correlation between tumor uptake and tumor 
microvessel density and reveal remarkable heterogeneity in 
liposomal tumor accumulation. Based on the preclinical data, 
one would predict that the efficacy results of clinical studies 
with stable nanomedicines such as PLD could have been much 
improved by selection of a patient population with high EPR 
tumors. By imaging the fate of the nanoparticles, the EPR-
dependent tumor uptake of the drug payload can be predicted 
in each specific case and correlated with the clinical response. 
This would provide direct clinical data to determine whether or 
not selecting patients based on the EPR characteristics of their 
tumor could lead to improved therapeutic benefit of PLD or any 
other nanoparticle-based therapy (46, 47).
Another aspect of nanomedicines that has not been addressed 
in clinical studies is the interaction with the immune system. 
Future clinical studies should incorporate immunopharmacologic 
tests to gain an insight on these interactions. With liposomes, 
immunomodulation can occur at least at two different levels:
 1. The CARPA reaction has been described in the preceding 
section of this article. While nanoparticle-induced blood 
complement activation may be common in patients, CARPA 
seldom manifests clinically in patients treated with PLD when 
infusion protocols are carefully followed (11). Nonetheless, we 
do not know the incidence of subclinical complement activa-
tion and whether it may affect the immune system in the local 
tumor environment.
 2. Macrophage function is a major factor in liposome clearance. 
Liver and spleen macrophages determine systemic clearance, 
and local tissue macrophages in tumors and other tissues are 
also important scavengers of extravasated liposomes. Based 
on this, peripheral blood monocytes have been proposed as 
a surrogate marker that can predict macrophage-mediated 
liposome clearance (14). Importantly, nanomedicines that 
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suppress or activate macrophages either due to carrier-related 
effects or drug-specific effects may have direct and/or indirect 
consequences blunting or boosting the ultimate antitumor 
effect observed.
FUtUre OUtLOOK
A key roadblock in the development of efficacious cancer thera-
pies is the systemic toxicity of the majority of these agents. Drug 
delivery using nanoparticle carriers has been an important and 
valuable strategy in overcoming this challenge by dramatically 
improving the tolerability of anticancer drugs in patients (48). 
However, this approach has not yet achieved a sound improve-
ment in clinical efficacy as predicted from its pharmacologic 
advantages. We propose that the immune system is a key player in 
the pharmacology of nanoparticle-based therapy, probably more 
so than for conventional low molecular weight drugs, and that 
new understanding of the mechanisms of immune modulation by 
nanoparticles and their associated drug cargo can lay the founda-
tion for future work that will realize the full clinical potential of 
cancer nanomedicines.
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